Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

evolocumab

evolocumab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Repatha SOLUTION, SUBCUTANEOUS 140 mg      
Comments:

Non-formulary, not stocked.  This is a PCSK9 inhibitor used for lowering cholesterol (LDL) and given sub Q q 2 weeks or q 4 weeks.  Defer use to outpatient therapy.  Upon discontinuation, LDL levels slowly return to baseline over several weeks.

Reviewed: 28 October 2015 (Repatha)

Last updated: May. 18, 2017






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved